跳转至内容
Merck
CN

SML0042

Sigma-Aldrich

Lazabemide hydrate

≥97% (HPLC)

登录查看公司和协议定价

别名:
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate
经验公式(希尔记法):
C8H10ClN3O · xH2O
分子量:
199.64 (anhydrous basis)
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥97% (HPLC)

形式

powder

储存条件

desiccated

颜色

white to tan

溶解性

DMSO: ≥22 mg/mL

创始人

Roche

储存温度

room temp

SMILES字符串

O.NCCNC(=O)c1ccc(Cl)cn1

InChI

1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2

InChI key

JYWYNPKXSLPWGV-UHFFFAOYSA-N

应用

Lazabemide hydrate may be used in cell signaling studies.

生化/生理作用

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease and in combination with nicotine replacement therapy aids in smoking cessation.

特点和优势

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

V Petegnief et al.
Neuroscience, 94(1), 105-115 (1999-12-29)
Previous data from our laboratory indicate that 25 mM ibotenic acid induces intracellular calcifications in the rat basal forebrain. Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
A M Cesura et al.
Advances in neurology, 80, 521-528 (1999-07-20)
R Raddatz et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 1135-1145 (2000-02-25)
A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in
Clinical trials of neuroprotection for Parkinson's disease.
Peter A LeWitt
Neurology, 63(7 Suppl 2), S23-S31 (2004-10-13)
Javier Ballesteros et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 18(1), 55-61 (2007-06-16)
Previous studies have reported negative findings for the association among brain monoamine oxidase B (MAO-B) and suicidal behaviour. However those studies did not adequately control their main results for the influence of confounding variables such as age at death. We

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门